Search

Coccidioides immitis spherule

Coccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.

Vonicog alfa

[A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation. … [A264389] Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.[A264389]

Icaridin

Icaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595]. … Icaridin, also known as Picaridin or hydroxy-ethyl isobutyl piperidine carboxylate, is a cyclic amine and a member of the piperidine chemical family.

Metixene

Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.

Fibroblast growth factor-1

Aminohippuric acid

Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

Sodium bisulfite

Sodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.

Aprepitant

Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting … Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.

Tienilic acid

It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982) … Tienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension.

Levacetylleucine

Levacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo. … , after which animal studies showed that the L-enantiomer (i.e. levacetylleucine) has potential clinical benefits compared to the racemic mixture.